Trastuzumab biosimilar - EirGenix

Drug Profile

Trastuzumab biosimilar - EirGenix

Alternative Names: EG12014

Latest Information Update: 13 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EirGenix
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 May 2017 EG 12014 is available for licensing as of 12 May 2017.
  • 04 May 2017 EirGenix completes a phase I trial in Breast cancer (In volunteers) in Europe
  • 04 May 2017 EirGenix plans a phase III global study for Breast cancer in USA and European Union countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top